Jim Cramer - Mad Money Dexcom DXCM-Q DON'T BUY Aug 07, 2024

He regrets he didn't sell some of his oil holdings today. He doesn't see the price of oil moving up from here, but will move down.

Does well when (sadly) diabetes is booming. The fear is that drugs develop from Novo Nordisk and Eli Lilly will cut down on diabetes. He tends to agree. Be careful here.

DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free

Their last quarter was very bad. He lost faith.